Axial Therapeutics to Participate in a Fireside Chat Hosted by LifeSci Capital
WALTHAM, Mass. -- Axial Therapeutics Inc., a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that company management will participate in a fireside chat hosted by LifeSci Capital on Tuesday, November 17, 2020 at 1:00 PM ET.
About Axial Therapeutics
Axial Therapeutics is a clinical-stage, biopharmaceutical company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of the central nervous system and other gut-derived diseases. The Company has built a pipeline of novel small molecules with lead programs to address the significant unmet patient needs associated with Parkinson’s Disease and Autism Spectrum Disorder.
Related news
-
Bayer receives positive CHMP opinion for finerenone as a new treatment for adult patients with chronic kidney disease associated with type 2 diabetes
Finerenone, a non-steroidal, selective mineralocorticoid receptor (MR) antagonist, is recommended by CHMP for marketing authorization for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) CHMP opinion is based on the results of the Phase III FIDELIO-DKD study investigating the efficacy and safety of finerenone on kidney and cardiovascular outcomes in patients with CKD associated with T2D Final European Commission decision is expected in the coming months The Committee for...
-
Phase III trial with Nubeqa (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
ARASENS trial demonstrates an increase in overall survival evaluating darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) compared to docetaxel and ADT, a standard of care in metastatic hormone-sensitive prostate cancer (mHSPC) / Bayer plans to present these pivotal data at a forthcoming scientific congress and to discuss them with health authorities / ARASENS is part of broad development program for darolutamide which includes another ongoing Phase III trial in mHSPC, ARANOTE,...
-
CD Formulation: A New Contract Service Organization of Solid Dosage Form Development for Pharmaceutical Industry
Earlier this month, CD Formulation announced the launch of solids dosage forms development service. As a leading excipient manufacturer and formulation development CRO, since its establishment, CD Formulation has always focused on expanding its products and services to meet the growing pharmaceutical needs of customers around the world and to promote the growth of the global pharmaceutical industry. The solid dosage form is of vital importance for pharmaceuticals, which accounts for about 70% of the preparations...
-
Lonza and Sheba Medical Center Use Cocoon® Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy
Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon® automated manufacturing Platform The data underscores the capability of Cocoon® to successfully manufacture immunotherapies at the point-of-care Three patients had complete responses, with another patient still under evaluation Tel Aviv, Israel and Basel, Switzerland, 12 August 2021 – Sheba Medical Center at Tel Hashomer, the largest hospital in the...
-
BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson`s Disease
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly owned subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DA01 for advanced Parkinson’s disease (PD). DA01, BlueRock’s pluripotent stem cell-derived dopaminergic neuron therapy, is under evaluation in a Phase 1 study. The FDA’s Fast Track designation is intended to facilitate the development and review of drug candidates that treat serious condition...
Customer comments
No comments were found for Axial Therapeutics to Participate in a Fireside Chat Hosted by LifeSci Capital. Be the first to comment!